To the Editor: I read the intriguing report by Andrew F. Leuchter et al., M.D. (1), of a comparison of brain quantitative electroencephalography (QEEG) in depressed subjects who received placebo and in those who received an antidepressant (fluoxetine or venlafaxine). For unknown reasons, the authors described the collection of QEEG measures at the end of the 1-week placebo lead-in period (1 week after baseline) but neglected to report these data.